Hoofd-halstumoren : aanpak in 2011
Faculty of Medicine and Health Sciences
Nederlands tijdschrift voor oncologie. - Amsterdam, 2004, currens
, p. 51-58
University of Antwerp
The management of head and neck cancer is complex and requires a multidisciplinary approach involving multiple specialists with a particular interest and expertise in the disease. Single-modality treatment with surgery or radiotherapy is generally recommended for the approximately 40% of patients who present with stage I or II disease. For the 60% of the patients who present with locally advanced disease at diagnosis, combined modality therapy is generally recommended. For patients with unresectable disease the current standard treatment is concurrent cisplatin-based chemoradiation. This is also the standard for patients with resectable disease when organ preservation is desired. The role of induction chemotherapy remains controversial. Recurrent and metastatic squamous cell head and neck cancer still carries a poor prognosis. There is now a plethora of targeted therapies in various stages of preclinical and clinical development. So far, the data on the epidermal growth factor receptor directed monoclonal antibodies seem to be more promising in their interaction with cytotoxic agents and radiotherapy.